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ABSTRACT 
The estrogen receptor (ER) and progesterone receptor (PR) are over-expressed in ~50% of breast 
cancer lesions, and used as biomarkers to stratify patients to endocrine therapy. Currently, 
immunohistochemical (IHC) assessment of these lesions from core-needle biopsy in deep-sited 
metastases has limitations associated with sampling error and lack of standardization. An alternative 
solution is positron emission tomography (PET)-based probes, which are inherently quantitative and 
capable of imaging the entire tumor, including metastases. This work features the synthesis and 
biological evaluation of a novel fluorinated derivative of Tanaproget, a high affinity non-steroidal PR 
ligand, as a candidate for imaging PR expression in vivo. Radiolabeling of the candidate was achieved 
in a 15% 4 radiochemical yield (non-decay corrected) in one step from [18F]fluoromethyltosylate in 
30 min. Cell uptake studies showed a significant difference between the radioligand uptake in PR+ 
and PR– cell lines; however, in vivo imaging was confounded by defluorination hypothesized to occur 
via iminium salt formation. Investigation into high affinity, metabolically stable non-steroidal PR 
ligands is currently ongoing. 
 
 
 
 
 
INTRODUCTION 
Steroid hormone receptors (SHR) regulate cellular function in healthy tissue, however, over-activation 
of some SHRs promote the proliferation of hormone-responsive cancer.1 A definitive example, 
endogenous estrogen binding to the estrogen receptor (ER), triggers tumor proliferation in 70 – 80% 
of cases of breast cancer and 33 – 53 % of ovarian cancers.2-3  Progesterone receptor (PR) expression 
is regulated by the ER and can consequently behave as a surrogate biomarker to report on ER 
function. As a result, ER and PR expression have predictive and prognostic importance, allowing 
patients to be stratified into responders/non-responders of endocrine therapy, the frontline treatment 
for ER+ tumors.4 The current gold standard for assessment of ER/PR expression is ex vivo 
immunohistochemistry (IHC) which is prone to misrepresent heterogeneity of receptor expression.5-7 
Positron emission tomography (PET) may overcome the limitations of IHC by quantifying receptor 
expression in metastatic lesions where biopsy sampling is challenging, while also accounting for 
heterogeneous receptor expression in primary disease. The use of the ER-targeted radioligand, 16α-
[18F]fluoro-17β-estradiol ([18F]FES), shown in Figure 1, has been successful in many clinical trials 
involving primary and metastatic breast cancer.8-18 Further integration of [18F]FES-PET into routine 
clinical experience is hampered by rapid metabolism and the difficulty of imaging patients receiving 
endocrine therapy owing to competition for ER between the radioligand and the therapeutic agent.19 
This has prompted investigation into PR targeted radioligands to report on the presence of a functional 
ER pathway. 21-[18F]Fluorofuranyl-norprogesterone ([18F]FFNP) (Figure 1) has been used 
successfully to image PR expression in a clinical trial, as well as pre-clinical studies to determine if 
[18F]FFNP could report on response to endocrine therapy.20-22Although studies into [18F]FFNP as a 
radioligand for imaging PR expression have been promising, its physicochemical properties, e.g., high 
LogP associated with the steroidal structure of the ligand may compromise specificity for PR binding.
  
 
Tanaproget (Figure 1) is a high affinity, highly specific, non-steroidal PR agonist (EC50 = 0.15 nM) 
developed by Wyeth as an orally bioavailable contraceptive.23 Tanaproget derivatives have previously 
been investigated for use as radioligands where derivatization at the R2-position provided racemic 
[18F]fluoropropyl-tanaproget([18F]FPTP) (Figure 1), which showed promising results in preliminary in 
vivo studies.24-25 Subsequently, [18F]FPTP was synthesized in a 5% yield (decay corrected) with a 
specific activity >20 GBq/µmol; tissue biodistribution was evaluated in immature estrogen-primed 
female rats and proved to exhibit favorable target distribution with high uptake in uterus and reduced 
uptake in bone compared to [18F]FFNP.25 [18F]FPTP was evaluated as a racemic mixture despite 
computational studies showing that the S-enantiomer was likely to adopt the lowest energy 
conformation in the PR ligand-binding domain; therefore, the racemic mixture is likely to contain two 
ligands exhibiting different  affinities.24 Structures of 18F-labeled PR compounds in the literature are 
shown in Figure 1A.24-27 The relative binding affinities (RBA) of Tanaproget and related 18F-labelled 
scaffolds are shown in Figure 1B. 
 
Figure 1. A. Structures of 18F-labelled PR compounds in the literature.22-23, 25-26 B. Relative Binding 
Affnity (RBA) of fluorinated Tanaproget derivatives obtained from competitive PR assays where the 
standard progestin R5020 is given a value of 100; R1& R2 = fluoroalkyl substituents; X = O or S.23 
In the same report, Zhou et al. also investigated fluoroalkyl- substitution at the N-pyrrole position 
where derivatization would not introduce a chiral center. Fluoroethyl and fluoropropyl derivatives 
were synthesized and evaluated for PR binding affinity (data summarized in Figure 1B).24 The affinity 
data reported by Zhou and co-workers indicates an inverse relationship between fluoroalkyl chain 
length and PR binding affinity. Based on this observed trend we reasoned that N-fluoromethyl-
alkylation could provide a radioligand with improved PR binding affinity. [18F]Fluoromethyltosylate 
is a versatile prosthetic group for which our group recently published an automated, cassette based 
and HPLC free GMP compatible radiosynthesis.28 Further motivation to explore radiolabeling at the 
N-pyrrole position included the opportunity to conserve the gem-dimethyl substitution at the R2-
position on the core scaffold, eliminating the chiral center formed in [18F]FPTP. Removing chirality 
from the radioligand a) precludes competition between enantiomers exhibiting different affinities for 
PR, which may have a confounding effect on receptor quantification and b) also precludes any 
requirement for chiral purification and QC analysis. Furthermore, analysis of the SAR from the 
development of Tanaproget suggested that the thiocarbamate is involved in determining biological 
profile of the ligand (agonist or antagonist) but does not assist in the formation of important hydrogen 
bonds to aid ligand binding. This observation, combined with evaluation of the available reports from 
the Wyeth group, furnished the conclusion that the thiocarbonyl was not strictly necessary for high PR 
binding affinity but rather “flipped” agents from antagonist to agonist, although this is not a strictly 
observed rule of thumb.23 As PET uses concentrations of radioligand that typically obey the tracer 
principle, biological profile (agonist/antagonist) of a lead candidate is deprioritized in favor of other 
desirable design properties, therefore we hypothesized that the thiocarbonyl may be dispensable in 
favor of a more synthetically accessible simple carbamate. Removal of the thiocarbamate 
functionality was considered favorable as its presence could hinder reaction progress when 
electrophilic reactive groups (e.g. alkylating agents) are used for the radiolabeling step; carbamates 
are less susceptible to electrophilic attack. Furthermore, replacement of the thiocarbamate with a 
simple carbamate would eliminate the need to convert the carbonyl to the thiocarbonyl post-
radiolabeling; this has previously been achieved by using Lawessons reagent as reported by Zhou et 
al. in the radiosynthesis [18F]FPTP.25 Herein we describe the synthesis and evaluation of a Tanaproget 
derivative that features facile access to a radiolabeling precursor and a simple radiolabeling strategy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
Synthesis of the reference compound (6). The reference compound 6 was tested for PR potency to 
verify our hypothesis concerning probe design (prior to any radiolabeling); chemical methodology is 
described in Scheme 1. 6-Bromo-4,4-dimethyl-1,4-dihydrobenzo[d][1,3]oxin-2-one 2, was coupled 
with N-boc-pyrrole boronic acid using a palladium-catalyzed Suzuki reaction to give 3 in a moderate 
yield of 47%. Subsequent cyanation of the pyrrole at the 5-position using chlorosulfonylisocyanate 
(CSI) and subsequent thermolysis to remove the protecting group gave precursor 5 efficiently in 31% 
over two steps. Alkylation of the N-H pyrrole nitrogen with fluorobromomethane gave the desired 
compound 6 in a yield of 19% under basic conditions in DMF.  
 
 
 
 
 
 
 
Scheme 1.Preparation of reference compound 6. (a) N-boc pyrrole boronic acid, Pd(PPh3)4, K2CO3, 
EtOH, toluene, H2O, 80°C, 16 h. (b) CSI, THF, -78 °C, 90 min, then DMF, RT, 16 h. (c) N2, 170 °C, 
20 min. (d) fluorobromomethane, K2CO3, DMF, RT, 16 h. 
Radiolabelling compound 6. The prosthetic group [18F]fluoromethyltosylate has been routinely 
synthesized within our laboratory starting from methylene ditosylate.28 From there, coupling to the 
nitrogen on the pyrrole ring was achieved using K2CO3 in DMF at 150 °C in an isolated radiochemical 
yield of 15% 4 (n = 20, non-decay corrected) (Scheme 2). Temperatures of 25 °C, 90 °C and 110 
°C were all studied, but gave minimal radiochemical incorporation (<1% by analytical HPLC), whilst 
the reaction did not proceed as cleanly without the presence of K2CO3 as a base, with up to two other 
radiochemical peaks noted in the absence of K2CO3. The product was isolated using semi-preparative 
HPLC and reformulated into ethanol, before being diluted down using saline solution to less than 5% 
ethanol content in the formulated mixture. Specific activity was routinely found to be between 10 and 
20 GBq. Radiochemical stability of > 99% was found upto 4 hours in ethanol and saline 
independently. 
 
 
  
 
 
 
 
 
Scheme 2. Radiolabelling of precursor 5. (a) [18F]fluoromethyltosylate, K2CO3, DMF, 150°C, 30 min. 
 
PR receptor interaction. The cell-free PolarScreen™ PR competitor assay was used to 
determine the half-maximal PR competitive binding affinity, IC50, and therefore the relative binding 
affinity (RBA; relative to progesterone).  Compound 6 had an IC50 of 29.9  10.2 nM (Figure 2); the 
RBA of 6 was 127.5% when compared directly to progesterone. Taken together, the affinity data 
demonstrate that compound 6 has high affinity for PR and is suitable for further evaluation as a PET 
probe. It should be noted, however, that at low concentrations, progesterone had non-linearly lower 
affinity for PR. This may be a relevant consideration when compound 6 is used at the typical low 
concentrations for PET imaging against a background of variable progesterone levels in nude and 
haired laboratory mice (2-22 ng/mL).  
 
Figure 2. Determination of the relative PR-binding using a cell-free fluorescence polarization assay. 
Progesterone (filled triangles) and compound 6 (filled squares) were tested. 
Binding specificity. Compound 6 was studied for cross-reactivity to other steroid receptors including 
GR, AR and ER using luciferase reporter assays (Figure 3). Dexamethasone, a GR ligand exhibited 
high luciferase activity in keeping with activation of GR reporter; MPA (medroxyprogesterone 
acetate), a potent progesterone agonist, had minimal GR activity while compound 6 showed negligible 
activation of GR (Figure 3). DHT interacted with AR with ~10-15-fold activation at concentrations up 
to 1 µM.  MPA and compound 6 increased AR activation by ~2.5-fold at 1 µM. In the ER luciferase 
reporter assay, compound 6 and MPA activated the receptor by approximately 2-fold less than 
estrogen (Figure 4). These assays demonstrated high specificity of compound 6 for PR (low non-
specific interaction with related receptors). 
 
Figure 3. Specificity of binding. Compound 6 together with relevant controls were tested to 
determine specificity for A. GR, B. AR or C. ER. MPA, Medroxyprogesterone acetate. RLU, Relative 
light units using firefly luciferase; in the case of A, the RLU of firefly luciferase to that of renilla 
luciferase was determined (thus, RLU ratio).  
In vitro cell uptake study. Subsequently, in vitro uptake experiments were carried out using [18F]6 in 
three breast cancer cell lines – MCF7, MDA-MB-231 and T47D - with different PR expression 
(Figure 4A). Uptake of [18F]6 correlated with PR expression determined by western blotting. T47D 
cells showed highest PR- and PR- expression followed by MCF-7; PR expression was undetectable 
in MDA-MB-231 cells. The uptake of [18F]6 was determined in these cell lines under estrogen-
induced conditions. The uptake of [18F]6 (Figure 4B) was associated with PR expression determined 
from the western blots. Of note, [18F]6 was non-negligible in MDA-MB-231 cells demonstrating 
some degree of non-specific interaction in this PR negative cell line. To further verify specificity, we 
incubated T47D cells with varying levels of progesterone to block the receptor prior to addition of 
[18F]6 (Figure 4C). By progressively increasing the dose of progesterone up to 10 M, uptake of 
[18F]6 decreased to one third of its original value, demonstrating that [18F]6 uptake was broadly 
specific to the PR ligand binding.  
 
Figure 4. Uptake of [18F]6 in cells with varying PR expression. A. PR expression in the presence or 
absence of estrogen (E) as determined by western blot. -actin was used as load control. B. Uptake of 
[18F]6 in the different cell lines. C. Blocking of [18F]6 uptake in T47D cells pre-treated with varying 
concentrations of progesterone. 
As further validation to understand the context of binding (antagonist vs agonist), we synthesized 
[11C]tanaproget according to our previously published methodology29 (Figure 5A) and performed 
uptake studies in PR positive and negative cells. The magnitude of uptake of [11C]tanaproget in the 
cells was broadly similar to that seen with [18F]6 (Figure 5B). Surprisingly, blocking with 
progesterone or unlabeled tanaproget led to an increase rather than a decrease in [11C]tanaproget-
uptake. This led us to question whether uptake of [11C]tanaproget was modulated by Multi-Drug 
Resistance (MDR) protein interaction and hypothesise that self-blocking could be abolished when 
MDR mechanism is inhibited/saturated with a modulator. Treatment of cells with verapamil, a P-gp 
inhibitor, increased uptake by approximately 30%, supporting a role for MDR (Figure 5C). Similar 
increases in calcein (an MDR substrate) uptake in the cell lines following pre-treatment with 
progesterone or tanaproget corroborated the radioligand uptake studies (Figure 6D). It is important to 
note that a >15-fold higher concentration of verapamil was required to increase [11C]tanaproget 
uptake compared to unlabeled tanaproget or progesterone. The specific reason for this is not known 
but could be due to the a more efficient inhibition of P-gp by progesterone compared to verapamil 
reported in some studies, differential  specificity of [11C]tanaproget for multidrug resistance proteins 
[P-glycoprotein (P-gp; MDR1), multidrug resistance-associated proteins (MRP1, MRP2, MRP3, 
MRP4, and MRP5), and breast cancer resistance protein (BCRP)] or differential expression of these 
proteins in MDA-MB-231 and T-47D cells.30 
 Figure 5. Uptake of isotopically labelled [11C]tanaproget in cells. A. Synthesis of [11C]tanaproget. B. 
Uptake of [11C]tanaproget in PR-proficient and PR-deficient cell lines, in the presence or absence of 
blocking dose of tanaproget or progesterone. C. Effect of verapamil on [11C]tanaproget uptake. D. 
Effect of the same chemical modulators in used C on uptake of calcein-AM (effect on multidrug 
resistance protein interaction). 
In vivo evaluation of [18F]6. In vitro experiments indicated the potential for [18F]6 to be a candidate 
radioligand for PR imaging; therefore, in vivo imaging was studied in mice bearing T47D xenografts. 
Summed images 30-60 minutes post-injection from 60 minute dynamic PET scans using [18F]6 and 
[18F]FDG are shown in Figure 6. These indicate a viable tumor ([18F]FDG scan) but marginal 
selective uptake for [18F]6. This is further confirmed by comparison of uptake in tumor for [18F]6 and 
[18F]FDG shown in Figure 6C. The time activity curve of [18F]6 (Figure 6B) showed a gradual rise in 
bone localization over the course of the imaging sequence, almost trebling between 5 and 60 min. The 
maximal uptake in bone from biodistribution (-counting) studies was 17.5 % ID/g at 60 min (Figure 
7A). This suggest in vivo defluorination of [18F]6. Liver uptake was also high (20.3 % ID/g) (Figure 
7A).  
 
Figure 6. Imaging studies with [18F]6 and [18F]FDG. A. Axial and sagittal PET images of [18F]6  and 
[18F]FDG 30-60 post-injection. B. Time activity curves of both radiotracers in different organs and 
tumor N=3 animals. C. Quantitative comparison of tumor uptake of [18F]6 and [18F]FDG (N=3 
animals per group; p < 0.0001). 
 
 Figure 7. Normal tissue biodistribution and in vivo metabolism of [18F]6. A. Biodistribution of [18F]6 
in different organs at 60 min after intravenous injection. B. Radio-HPLC chromatograms of [18F]6 in 
different tissues at 60 min post intravenous injection.  
Defluorination assay. To confirm the hypothesis that bone uptake was a result of [18F]6 
defluorination, we carried out a metabolite assay by taking fractions at 60 min of selected organs and 
analyzing via radio-HPLC (Figure 7). In each sample, apart from the reference compound (parent Rt = 
5.5 minutes), [18F]fluoride (Rt = 2 minutes, by comparison with [18F]fluoride direct from the cyclotron 
under the same chromatographic conditions), and a second metabolite (Rt = 4 minutes) were seen 
(Figure 7B). In particular, circulating plasma contained more than 50% of the activity as [18F]fluoride 
at 60 min, this supports the notion that defluorination correlates with bone uptake. A summary of the 
proportions of radio-analytes are shown in Table 1. 
 
 
 
 
Sample (n = 3) [18F]Fluoride/% Metabolite/% [18F]6/% 
[18F]6 reference - - 99 ± 1 
[18F]Fluoride reference 99 ± 1 
  
Urine 65 ± 3 25 ± 2 10 ± 4 
Plasma 55 ± 5 - 45 ± 5 
Liver 13 ± 3 5 ± 1 82 ± 2 
Small intestine 
contents 
8 ± 4 11 ± 4 81 ± 2 
 
Table 1.  Fraction of [18F]6 remaining after 60 min (n=3 for each sample). 
Examining previously described work, Jehangir et al had reported the formation of highly reactive 
iminium salt from 1-fluoro-N,N-dimethylmethanamine which is analogous to [18F]6, with a similar 
defluorination mechanism possible (Scheme 3A).31 Although no fluoride was ever seen in a 
formulated sample of [18F]6 after 4 hours, it seems likely that any number of factors present in vivo, 
such as variations in pH above and below 7, could push the mechanism to a dissociated [18F]fluoride 
as shown in Scheme 3.31 
 
 
 
 
 
Scheme 3. A) Defluorination of 1-fluoro-N,N-dimethylmethanamine.30 B) Hypothesized mechanism 
for the defluorination of compound [18F]6 by iminium salt formation. 
 
DISCUSSION 
Steroid-derived PET imaging agents such as [18F]FDHT (AR), [18F]FES (ER) and [18F]FFNP (PR) 
continue to generate interest for patient stratification to inform treatment regimen planning. Four 
A.  
B.  
decades of research into SHR imaging agents have resulted in the formulation of important criteria for 
developing successful imaging agents. The rate of attrition of SHR imaging candidates is attributed to 
poor receptor specificity, unfavorable biodistribution and rapid metabolism, characteristics that can 
generally be associated with steroidal compounds. More recently, investigation of non-steroidal SHR 
imaging agents to circumvent these negative characteristics have identified promising compounds 
particularly in the case of PR targeted radioligands.32 Lee et al. (2010) synthesized tanaproget 
derivative [18F]FPTP which has shown potential by successfully imaging PR expression in vivo. 
Although [18F]FPTP is a promising candidate radioligand, we proposed an alternative derivative 
([18F]6) for investigation.  
We speculated that [18F]6 would exhibit a high affinity for PR based on SAR observations in the 
literature.24 The synthesis of the precursor for [18F]6 involved relatively a five step synthesis with an 
overall yield of 6%. The radiolabeling procedure of [18F]6 was simplified compared to [18F]FPTP as 
our design criteria removed the requirement of further structural modifications post-labeling. We 
postulated that the agonist/antagonist binding mode for the imaging agent could be de-prioritized 
because concentration of compound administered would be too low to perturb the biological system; 
based on this assumption, converting [18F]6 from the carbamate to thio-carbamate was not necessary.  
Radioligand [18F]6 was synthesized in 120 min from end of bombardment (EOB) in a one-step 
procedure from [18F]fluoromethyltosylate which was faster than [18F]FPTP, synthesized in 140 min 
from EOB. The relative simplicity of the radiochemistry of [18F]6 was considered to be advantageous 
if the procedure was to be automated for routine pre-clinical/clinical production; [18F]FPTP required a 
more challenging procedure due to post-labeling conversions and as a result, automation of the 
radiosynthesis would be challenging. 
Compound [18F]6 was shown to bind the PR with a low nanomolar affinity and exhibited negligible 
cross-reactivity to the GR even at 100-fold concentration of ligand. In vitro evaluation of [18F]6 was 
successful in showing significant uptake in PR+ cells that could be blocked with substrates selective 
for the PR ligand binding domain (LBD). This confirmed that [18F]6 binds the same receptor LBD as 
known steroidal progestins and not an allosteric site. These were encouraging results as they 
supported the assumption of deprioritizing binding profile in favor of more important characteristics. 
In vivo performance of [18F]6 was investigated in both T47D xenograft bearing mice and normal 
female mice; however, tumor uptake of [18F]6 was poor which was likely to be the result of 
insufficient metabolic stability over the imaging time-frame. Extensive defluorination (17.5 % ID/g in 
bone) was observed at 60 min, which we propose is facilitated by iminium salt formation (Scheme 3). 
Furthermore, it may be possible that the low nanomolar affinity of [18F]6 was sufficient to observe 
selective uptake in an in vitro cell model but may be insufficient for imaging in vivo PR expression. 
Most steroid-based PR ligands exhibit sub-nanomolar affinity and it may be the case that, similarly 
high affinity is required for non-steroidal imaging ligands. An avenue of interest for further research 
is the development of higher affinity PR ligands, which could potentially be achieved using a 
medicinal chemistry based fragment screening campaign. The specific activity of [18F]6 was 
estimated to be about 10 GBq/mol. In a mouse weighing 20g this would equate to a dose of cold 
[19F]6 estimated at ~2.8 g/kg, well below the level of a therapeutic dose which would be expected in 
the range of 1 mg/kg or above. Therefore, the imaging protocol complied with the concept of the 
“tracer principle” and the mode of binding (agonist or antagonist) could be discounted as a factor in in 
vivo performance of the [18F]6. 
Tanaproget served as a useful starting point for developing PR imaging agents investigated herein and 
previously, however, we have shown that even with careful consideration when derivatizing the 
structure, deviation from sub-nanomolar affinity and poor metabolic stability can hinder the 
development of an effective in vivo imaging agent. Attracted by the sub-nanomolar affinity of 
tanaproget, we decided to investigate carbon-11 radiolabeled Tanaproget, accessed via a novel 
[11C]carbon disulfide pathway reported elsewhere.29 Given the high affinity of tanaproget for PR we 
were surprised by the poor performance of this agent in cell-uptake models. Inhibition of P-gp using 
verapamil partially reversed this phenomenon, indicating a role for cellular efflux proteins in 
localization of [11C]tanaproget. This therefore highlights another important consideration for the 
future development of non-steroidal PR imaging agents. 
It is prudent to evaluate the limitations of [18F]6 and how these characteristics can influence the future 
design of non-steroidal PR ligands.  From analysis of a previous study by Zhou and the results from 
this study, it is apparent that a number of design criteria are applicable to non-steroidal PR imaging 
probes. High PR selectivity (at least 100-fold over related SHRs) is of paramount importance. 
Successful clinical translation of a PR-targeted radioligand is dependent on accurate quantification of 
receptor expression to stratify patients and therefore cross-reactivity to other SHRs would confound 
imaging results. Radioligand [18F]6 was shown to be highly selective for PR over a panel of SHRs 
(AR, GR, ER). Sub-nanomolar affinity for PR is an important consideration; although [18F]6 was able 
to specifically detect PR expression in vitro, the presence of circulating endogenous steroid hormones 
in vivo may out-compete radioligands of lower affinity. Although [18F]6 did not exhibit sub-
nanomolar affinity, it performed well in in vitro binding assays. We are unable to confidently 
conclude if [18F]6 was of appropriate affinity to image PR due to fast metabolism of the radioligand. It 
should be noted that sub-nanomolar affinity is a high-ranking priority in PR ligand design but should 
not be used as a metric for extrapolating success of imaging PR in vivo. Radioligand [11C]tanaproget, 
is a non-steroidal PR ligand that exhibits sub-nanomolar affinity yet was had limited selectivity for PR 
in vitro. We have shown the importance of ensuring PR ligands are poor substrates for MDR proteins. 
The role of sex-hormone binding protein (SHBP) in the pharmacokinetics of steroidal SHR ligands 
(e.g. [18F]FES, [18F]FDHT) has long been studied; detailed evaluation of the role of MDR proteins 
may provide insight to influence ligand design going forward. One assumption we used for PR ligand 
design was the deprioritization of biological profile (agonist/antagonist binding mode). In this study, 
we showed that in vitro uptake of [18F]6 was not influenced by biological profile of the radioligand. A 
high priority for SHR imaging remains to be specific activity; at 10 GBq/μmol [18F]6, may not be 
high enough to image PR in vivo. In addition, the standard design criteria that are generally applicable 
in new PET probe design remain relevant.33-34  
In summary, [18F]6  was unsuccessful at imaging in vivo PR due to rapid metabolism, however, it is 
important to stress that the success of [18F]6 did not hinge on this factor alone and potentially, may 
have been confounded by other factors despite rapid metabolism. Exhibiting a 10-fold lower affinity 
than the literature suggests and an average specific activity, [18F]6 may not have had the necessary 
characteristics for imaging in vivo PR, despite its success in in vitro studies. 
CONCLUSION 
In conclusion, we have examined the synthesis of a radiotracer [18F]6 based upon the derivatization of 
tanaproget, and have shown that [18F]6 has good uptake in vitro for cell lines expressing PR, 
demonstrating that the uptake is specific for PR. Unfortunately, [18F]6 showed poor metabolic 
stability, with overriding bone uptake seen by the end of the imaging protocol, suggesting that this 
compound is not suitable for in vivo imaging in mice, and unless metabolism can be demonstrated to 
be species specific, will predict non-suitability in humans. Work is currently on-going to explore 
possible variations on the structure to give a more promising long-term candidate for in vivo PR 
imaging. 
EXPERIMENTAL PROCEDURES 
Radiosynthesis of [18F]6. [18F]Fluoromethyltosylate was synthesized as previously described, and 
was used after SPE trapping and elution with MeCN (200 L).28 [18F]Fluoromethyltosylate (on 
average, approximately 2 GBq starting from 3 GBq before drying) was added to 100 L of dry DMF 
containing compound 5 (5 mg) and K2CO3 (5 mg). The reaction mixture was heated at 150 °C for 30 
minutes before being cooled and diluted with 8 mL of 2:3 H2O:MeCN and injected on semi-
preparative HPLC (Phenomenex Luna C18, 250 × 10, 2:3 H2O:MeCN, 3 mL/min). The labelled 
product 6 was collected (Rt = 9 min) and subsequently reformulated using tC18 light SPE cartridge 
(prepared with 2 mL EtOH and 5 mL H2O) after being diluted with 10 mL of H2O. [18F]6 was eluted 
from the tC18 cartridge in EtOH (5 x 100 L fractions) with the most concentrated fractions being 3 
and 4, with a 10% (non-decay corrected) yield starting from [18F]fluoromethyltosylate. Analytical 
radioHPLC was carried out to confirm the compound (Gemini C18, 150 × 4.6, 1:1 H2O:MeCN, 1 
mL/min) with a Rt of 5.5 minutes. 
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ABREVIATIONS 
AR, androgen receptor; BCA, bicinchoninic acid; CSI, chlorosulfonylisocyanate; DMEM, Dulbecco’s 
Modified Eagle’s Medium; E2, estradiol; ER, estrogen receptor; [18F]FDG, 2-deoxy-2-[18F]fluoro-D-
glucose; [18F]FES, 16α-[18F]fluoro-17β-estradiol; [18F]FFNP,21-[18F]Fluorofuranyl-norprogesterone; 
[18F]FPTP, [18F]Fluoropropyl-Tanaproget; GR, glucorticoid receptor; IHC, immunohistochemical 
MPA, medroxyprogesterone acetate; PR, progesterone receptor; pRLTK, thymidine kinase promoter-
Renilla luciferase reporter plasmid; R5020, promegestone; RLU, relative light units; RBA, relative 
binding affinity; RIPA, radio-immunoprecipitation assay; SAR, structure activity relationship; SCID, 
severe combined immunodeficiency;  
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